Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carlos Roberto de Mello Rieder is active.

Publication


Featured researches published by Carlos Roberto de Mello Rieder.


Neurology | 2007

ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease

A. Di Fonzo; Hsin Fen Chien; M. Socal; S. Giraudo; Cristina Tassorelli; G. Iliceto; Giovanni Fabbrini; Roberto Marconi; Emiliana Fincati; Giovanni Abbruzzese; P. Marini; F. Squitieri; M.W.I.M. Horstink; Pasquale Montagna; A. Dalla Libera; Fabrizio Stocchi; Stefano Goldwurm; Joaquim J. Ferreira; Giuseppe Meco; Emilia Martignoni; Leonardo Lopiano; Laura Bannach Jardim; Ben A. Oostra; Egberto Reis Barbosa; Vincenzo Bonifati; Nicola Vanacore; Edito Fabrizio; N. Locuratolo; C. Scoppetta; Mario Manfredi

Objective: To assess the prevalence, nature, and associated phenotypes of ATP13A2 gene mutations among patients with juvenile parkinsonism (onset <21 years) or young onset (between 21 and 40 years) Parkinson disease (YOPD). Methods: We studied 46 patients, mostly from Italy or Brazil, including 11 with juvenile parkinsonism and 35 with YOPD. Thirty-three cases were sporadic and 13 had positive family history compatible with autosomal recessive inheritance. Forty-two had only parkinsonian signs, while four (all juvenile-onset) had multisystemic involvement. The whole ATP13A2 coding region (29 exons) and exon-intron boundaries were sequenced from genomic DNA. Results: A novel homozygous missense mutation (Gly504Arg) was identified in one sporadic case from Brazil with juvenile parkinsonism. This patient had symptoms onset at age 12, levodopa-responsive severe akinetic-rigid parkinsonism, levodopa-induced motor fluctuations and dyskinesias, severe visual hallucinations, and supranuclear vertical gaze paresis, but no pyramidal deficit nor dementia. Brain CT scan showed moderate diffuse atrophy. Furthermore, two Italian cases with YOPD without atypical features carried a novel missense mutation (Thr12Met, Gly533Arg) in single heterozygous state. Conclusions: We confirm that ATP13A2 homozygous mutations are associated with human parkinsonism, and expand the associated genotypic and clinical spectrum, by describing a homozygous missense mutation in this gene in a patient with a phenotype milder than that initially associated with ATP13A2 mutations (Kufor-Rakeb syndrome). Our data also suggest that ATP13A2 single heterozygous mutations might be etiologically relevant for patients with YOPD and further studies of this gene in Parkinson disease are warranted.


Journal of Biotechnology | 2011

Identification of blood microRNAs associated to Parkinsońs disease

Regina Margis; Rogério Margis; Carlos Roberto de Mello Rieder

The present study demonstrates that blood samples can be used as a source of miRNA identification associated to Parkinsons disease (PD). A set of six differentially expressed microRNAs were identified. They form two groups according to their expression profile in control, non-treated, early-onset and treated Parkinsons disease subjects. While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients. This study is innovative in contributing to the development of effective PD biomarkers.


Clinical Neuropharmacology | 2007

A double-blind, randomized, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm

Carlos Roberto de Mello Rieder; Pedro Schestatsky; Mariana P. Socal; Thais Lampert Monte; Daniele Fricke; João Costa; Paulo Dornelles Picon

There is a lack of evidence on the clinical efficacy and safety of the recently released Chinese botulinum toxin serotype A (Prosigne) for the treatment of focal dystonias and hemifacial spasm. Determining a more precise role of Prosigne in the treatment of such conditions is of paramount importance, because botulinum toxin type A treatments have a huge economic implication in health services, especially in developing countries. The aim of our study was to compare the efficacy and safety of Prosigne in the treatment of blepharospasm and hemifacial spasm in comparison to Botox. We performed a double-blind, randomized, crossover study enrolling 26 patients. There were no significant differences between Prosigne and Botox regarding subjective global improvement, response onset, efficacy duration, and incidence and severity of adverse events. Our results suggest that Prosigne and Botox are comparable with respect to efficacy and safety for the short-term treatment of blepharospasm and hemifacial spasm.


Parkinsonism & Related Disorders | 2009

Intrafamilial variability of Parkinson phenotype in SCAs: Novel cases due to SCA2 and SCA3 expansions

Mariana P. Socal; V.E. Emmel; Carlos Roberto de Mello Rieder; A. Hilbig; Maria-Luiza Saraiva-Pereira; Laura Bannach Jardim

BACKGROUND Parkinsons disease (PD) has been related to mutations associated with spinocerebellar ataxias (SCA); the frequency of the diagnosis of these mutations is low in general late-onset PD cases. Our aim was to investigate a selected high-risk group of PD patients. METHODS PD patients with autosomal dominant inheritance or atypical neurological manifestations were enrolled, underwent a full neurological examination and had the CAG tracts of their SCA1, 2, 3, 6 and 7 genes analyzed. RESULTS Of the 23 studied families, two SCA3 and one SCA2 cases were identified. All had autosomal dominant inheritance. In the SCA2 pedigree, four affected sibs had a homogeneous PD phenotype. CAG repeats varied between 35 and 44 with CAA interruptions. Intrafamilial phenotypic heterogeneity was identified in the SCA3 pedigrees; parkinsonian and ataxic phenotypes coexisted in both kindreds. CAGn varied between 69 and 71 repeats. Age of onset was lower in the SCA3 patients than in the remaining 24 cases (38 versus 46.7+/-12 years of age, p=0.003). CONCLUSIONS SCA2 and SCA3 mutations were detected in 13% of the present sample: the strategy of selecting a high-risk group increased the rate of making these diagnoses. The SCA2 cases confirmed an association between PD and interrupted expansions, as well as PD intrafamilial phenotypic homogeneity. Clinical heterogeneity of SCA3 pedigrees suggests that disease-modifying agents outside the MJD1 gene may play a role in determining PD symptoms in this disorder.


Annals of Neurology | 2016

DNAJC6 Mutations Associated with Early-Onset Parkinson's Disease

Simone Olgiati; Marialuisa Quadri; Mingyan Fang; Janneke P.M.A. Rood; Jonas Alex Morales Saute; Hsin Fen Chien; Christian G. Bouwkamp; Josja Graafland; Michelle Minneboo; Guido J. Breedveld; Jianguo Zhang; Frans W. Verheijen; Agnita J.W. Boon; Anneke J.A. Kievit; Laura Bannach Jardim; Wim Mandemakers; Egberto Reis Barbosa; Carlos Roberto de Mello Rieder; Klaus L. Leenders; Jun Wang; Vincenzo Bonifati

DNAJC6 mutations were recently described in two families with autosomal recessive juvenile parkinsonism (onset age < 11), prominent atypical signs, poor or absent response to levodopa, and rapid progression (wheelchair‐bound within ∼10 years from onset). Here, for the first time, we report DNAJC6 mutations in early‐onset Parkinsons disease (PD).


Movement Disorders | 2014

A Randomized, Phase 2 Clinical Trial of Lithium Carbonate in Machado-Joseph Disease

Jonas Alex Morales Saute; Raphael Machado de Castilhos; Thais Lampert Monte; Artur Schumacher-Schuh; Karina Carvalho Donis; Rui D'Ávila; Gabriele Nunes Souza; Aline Dutra Russo; Gabriel Vasata Furtado; Tailise Conte Gheno; Diogo O. Souza; Luis Valmor Cruz Portela; Maria-Luiza Saraiva-Pereira; Suzi Alvez Camey; Vanessa Leotti Torman; Carlos Roberto de Mello Rieder; Laura Bannach Jardim

Because lithium exerts neuroprotective effects in preclinical models of polyglutamine disorders, our objective was to assess the safety and efficacy of lithium carbonate (0.5‐0.8 milliequivalents per liter) in patients with Machado‐Joseph disease (spinocerebellar ataxia type 3 [MJD/SCA3]).


Public Health Genomics | 2007

Depressive Symptoms in Machado-Joseph Disease (SCA3) Patients and Their Relatives

C.R. Cecchin; A.P. Pires; Carlos Roberto de Mello Rieder; Thais Lampert Monte; Isabel Silveira; T. Carvalho; Maria Luiza Saraiva-Pereira; Jorge Sequeiros; Laura Bannach Jardim

Objectives: It was the aim of this study to determine the depression scores of Machado-Joseph disease (MJD) patients, their spouses, and individuals at 50% risk for MJD, and second, to verify the existence of a correlation between depressive symptoms and the degree of motor incapacitation. Subjects and Methods: Two hundred and forty-six individuals aged ≧18 years were studied: 79 MJD patients (group 1), 43 spouses of MJD patients (group 2), 80 individuals at risk for MJD (group 3), and a control group (group 4) composed of 44 patients with multiple sclerosis (MS). The following two tools were applied: the Beck Depression Inventory and the Barthel index of physical incapacitation, both in an adapted Brazilian Portuguese version. Results: Moderate to severe depressive scores were found in 33.5% of patients in the MJD families, in 16.3% of the spouses, and in 6.3% of the individuals at risk. This linear reduction between MJD family members was statistically significant (p < 0.0001, ANOVA). Depressive scores were also associated with age and the female sex. A direct correlation between Beck Depression Inventory scores and motor incapacitation was found in MJD patients (r = 0.507, Pearson correlation, p < 0.0001). Although the depressive symptoms in the control group with MS were higher than those found in MJD patients (59% of MS patients showed moderate to severe scores), depression did not correlate with physical incapacitation, age, or education attainment in the MS group. Conclusions: Depressive symptoms are rather common in MJD patients and in their spouses (caregivers). In this condition, depression seemed to be more reactive than primarily related to the disease process itself.


Movement Disorders | 2006

Hyperhidrosis in Parkinson's disease

Pedro Schestatsky; Josep Valls-Solé; João Arthur Ehlers; Carlos Roberto de Mello Rieder; Irenio Gomes

We studied the sudomotor skin response (SSR) in patients with Parkinsons disease with and without symptomatic hyperhidrosis. The study was carried out in 13 patients who complained of excessive sweating and in 37 patients who did not have excessive sweating. Patients were matched for age, sex, degree of impairment, duration of the disease, and number and severity of autonomic disturbances. Excessive sweating involved mainly the face, head, and trunk. The SSR was recorded from the palm of the hands to electrical stimulation of the median nerve at the wrist. We analyzed onset latency, peak to peak amplitude, and waveform. Patients with hyperhidrosis had more often absent responses (χ2 = 5.292; P = 0.021), their responses were of lower mean amplitude (analysis of variance [ANOVA]; F[2,101] = 11.678; P < 0.001), and they had a reduced number of responses with a predominantly negative component (χ2 = 8.493; P = 0.004) than patients who did not complain of sweating disturbances. Our results indicate that excessive sweating in Parkinsons disease concurs with decreased activation of sweat glands in the palms of the hands and suggests that axial hyperhidrosis could be a compensatory phenomenon for reduced sympathetic function in the extremities.


Acta Neurologica Scandinavica | 2003

Use of fluoxetine for treatment of Machado‐Joseph disease: an open‐label study

Thais Lampert Monte; Carlos Roberto de Mello Rieder; Adriano B. L. Tort; I. Rockenback; Maria Luiza Saraiva Pereira; Isabel Silveira; Anabela Ferro; Jorge Sequeiros; Laura Bannach Jardim

Context – Machado‐Joseph Disease (MJD/SCA3) is an autosomal dominant spinocerebellar degeneration that evolves to disability and death. Experimental data have shown that serotonin is an important cerebellar neurotransmitter and that impairment of the serotoninergic cerebellar system can induce cerebellar ataxia.


Metabolic Brain Disease | 2009

Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson´s disease

Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Ângela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Alex Morales Saute; Charles Rosa; Maria Julia Machline Carrion; Daiane Piccolotto Carvalho Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner

In the present work we measured blood levels of total homocysteine (tHcy), vitamin B12 and folic acid in patients with Parkinson´s disease (PD) and in age-matched controls and searched for possible associations between these levels with smoking, alcohol consumption, L-DOPA treatment and disease duration in PD patients. We initially observed that plasma tHcy levels were increased by around 30 % in patients affected by PD compared to controls. Linear correlation, multiple regression and comparative analyses revealed that the major determinant of the increased plasma concentrations of tHcy in PD patients was folic acid deficiency, whereas in controls tHcy levels were mainly determined by plasma vitamin B12 concentrations. We also observed that alcohol consumption, gender and L-DOPA treatment did not significantly alter plasma tHcy, folic acid and vitamin B12 levels in parkinsonians. Furthermore, disease duration was positively associated with tHcy levels and smoking was linked with a deficit of folic acid in PD patients. Considering the potential synergistic deleterious effects of Hcy increase and folate deficiency on the central nervous system, we postulate that folic acid should be supplemented to patients affected by PD in order to normalize blood Hcy and folate levels, therefore potentially avoiding these risk factors for neurologic deterioration in this disorder.

Collaboration


Dive into the Carlos Roberto de Mello Rieder's collaboration.

Top Co-Authors

Avatar

Laura Bannach Jardim

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Thais Lampert Monte

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Jonas Alex Morales Saute

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Maira Rozenfeld Olchik

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Artur Francisco Schumacher Schuh

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Karina Carvalho Donis

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Luis Valmor Cruz Portela

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Artur Schumacher-Schuh

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Maria Luiza Saraiva Pereira

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge